Navigation Links
VACUETTE® SRT 10/II

ProductsVACUETTE® SRT 10/II
Company Greiner Bio-One
Item VACUETTE® SRT 10/II
Features 
  • With 10 measuring channels
  • Time-saving due to prediction of measurement values
  • Printer connection
  • Optional thermal printer available
  • Auto test function
  • Tube throughput: 20 samples per hour
Description The NEW VACUETTE® erythrocyte sedimentation rate analysers, which are especially user-friendly, can help. The new generation unites the well-established advantages of the existing analysers with whole range of additional innovations which guarantee time-saving standardised analysis of the erythrocyte sedimentation rate. Cost effectiveness is an essential aspect of daily recurrent routine activities on the ward, in laboratories or in the doctor's practice. In order to increase efficiency on a long-term basis, a costeffective centralisation of the erythrocyte sedimentation rate analysis still remains an important step.
Info Greiner Bio-One
Customer Service: (800) 884-4703
Web site: http://www.greinerbioone.com/

Related medicine products :

1. VACUETTE® SRS 20/II
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
The Proteineer suite integrates powerful mass spectrometers with robotics and bioinformatics to deliver maximum productivity in high-throughput proteomics....
The ProteomeLab PA 800 resolves and quantifies proteins by their isoelectric point and molecular weight, generates high-resolution peptide maps and carbohydrate profiles and provides front-end separa...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Medicine Products:
(Date:4/21/2017)... ... ... broad access to life-saving drugs and rewarding the innovators who develop those drugs often ... , That was the message from Dana Goldman, PhD, Leonard D. Schaeffer Chair and ... who served as the keynote speaker for Western University of Health Sciences’ Ray Symposium ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between 2002 ... proportion of young people involved in violence in the United States. The study, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, ... to communities throughout the greater Pittsburgh metropolitan region, is joining forces with the ... bicycles for differently-abled children. , Variety the Children’s Charity is a national organization ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies ... project in the company’s esteemed VISION House demonstration project series. Manifesting the concept of ... of resources they need to live affordably and abundantly without unduly taxing the resources ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
Breaking Medicine Technology: